Pear Therapeutics (US)

Press Releases

Pear Therapeutics to Present at Jefferies 2018 Healthcare Conference

Boston, May 29, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5 at 2:30 p.m. EST at the Grand Hyatt New York.

Pear Therapeutics is a privately held prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious medical conditions.

About Pear Therapeutics

Pear Therapeutics is the leader in FDA-authorized prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead product, reSET®, is an FDA-authorized 12-week prescription therapeutic for Substance Use Disorder to be used as an adjunct to standard, outpatient treatment. Pear’s product development pipeline includes reSET-O™ for opioid use disorder and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat posttraumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive disorder, and insomnia. For more details, please see


Media and Investors:
Amanda Galgay